000			03885nam a2200397 i 4500
999			_c392219 _d392219
001			392219
003			ES-MaUEC
005			20231024130432.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			130802s2013 xxua o |||| 0|eng d
020			_a9781627035415
024	7		_a10.1007/978-1-62703-541-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS201 .A56 _b2013 EB
245	0	0	_aAntibody-Drug Conjugates _cedited by Laurent Ducry
250			_a1st edition 2013
264		1	_aTotowa, NJ _bHumana Press _c2013
300			_a1 recurso en línea (X, 317 páginas) _b96 ilustraciones, 42 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Biology _x1940-6029 _v1045
505	0		_aAntibody-Drug Conjugate (ADC) Clinical Pipeline: A Review -- Antibody-Drug Conjugate Target Selection: Critical Factors -- Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization -- Antibody-Drug Conjugate Payloads -- Linker Technologies for Antibody-Drug Conjugates -- In Vivo Testing of Drug-Linker Stability -- Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates -- Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment -- Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting -- Protocols for Lysine Conjugation -- Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers -- Enzymatic Antibody Modification by Bacterial Transglutaminase -- Formulation Development of Antibody-Drug Conjugates -- Conjugation Process Development and Scale-Up -- Methods for Conjugating Antibodies to Nanocarriers -- Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy -- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography -- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS -- Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF -- Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs).
520			_aAntibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs.  In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion.  Written in the highly successful Methods in Molecular Biology™ format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.   Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
988			_aSpringer_Protocols_2013
650		7	_2embne _9405730 _aAnticuerpos monoclonales
776	0	8	_iPrinted edition: _z9781627035422
776	0	8	_iPrinted edition: _z9781627035408
776	0	8	_iPrinted edition: _z9781493960262
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-62703-541-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b10/2023 _dz _eb _zSI